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Role of platelet activating factor in kidney transplant rejection in the
rat. Platelet activating factor (PAF) is a potent lipid mediator with a broad
range of biologic activities. Experimental evidence suggests that PAF plays
a role in the pathogenesis of a variety of inflammatory processes including
allograft rejection. In this study, we evaluated the effects of the PAF
antagonist BN52021 on the course of renal allograft rejection in a rat
model. Kidneys from AC! (RT1) rats were transplanted into fully
allogeneic PVG (RT1C) rat recipients. Animals received 60 mg/kg/day of
the PAP antagonist or vehicle beginning immediately prior to the trans-
plantation procedure. In rats treated with the PAP antagonist, allograft
GFR and plasma flow were maintained at levels that were significantly
greater than controls. Despite the improvement in renal allograft function,
BN52021 had no effect on allograft histomorphology and both groups
manifested intense inflammatory cell infiltration consistent with acute
cellular rejection. PAF antagonism reduced urinary excretion of throm-
boxane metabolites and decreased thromboxane production by homoge-
nates prepared from kidney allografts. The PAP antagonist had no effect
on urinary excretion of peptidoleukotriene metabolites or on the produc-
tion of LTB4 by allografts. These data support a role for PAP in the
pathophysiology of acute renal allograft rejection, and they suggest that
the hemodynamic effects of PAP during rejection may be mediated
through stimulation of thromboxane A2. In view of the beneficial effects of
PAP blockade in rejection as well as recent reports describing efficacy in
models of cyclosporine nephrotoxicity, PAP antagonists may have clinical
applications in human renal allograft recipients.
Kidney transplant rejection is triggered by the recognition of
donor MHC proteins by T cells from the host [1—3]. Recognition
of these foreign antigens triggers a cascade of responses that cause
graft cell injury through both specific and non-specific effector
pathways. This rejection response is characterized by infiltration
of organ grafts by a mixed population of inflammatory cells with
platelet aggregation, endothelial injury, and intense vasoconstric-
tion. In kidney graft rejection, there is intense vasoconstriction
and vascular disruption that cause acute reductions of glomerular
filtration rate and renal plasma flow, and eventually produce
ischemic damage [4—7]. Early clinical studies suggested that
vasoactive mediators might be important in causing these hemo-
dynamic effects [6]. Using animal transplant models, previous
studies by our group and others have demonstrated that a
substantial component of renal dysfunction and injury during
acute rejection is caused by lipid inflammatory mediators which
are produced as a part of the local alloimmune response [8—11].
Platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phos-
phocholine) is a lipid mediator that is synthesized through a
phospholipase A2 dependent pathway and is produced by a
number of cell types including macrophages, PMN's, vascular
endothelial cells, and glomerular mesangial cells [12—16]. This
autocoid exhibits a broad range of biological effects that may be
particularly pertinent to acute rejection. For example, PAF is a
potent chemotactic agent which increases vascular permeability,
enhances platelet aggregation, and promotes free radical forma-
tion [12—151. When infused systemically in vivo, PAP causes a dose
dependent fall in glomerular filtration rate and renal plasma flow
[12, 17, 181. However, a functional role of PAF in renal allograft
rejection has not been clearly defined.
The objective of the present study was to further define the role
of PAP in the pathophysiology of renal allograft rejection. We
first evaluated the effect of the potent and specific PAP antago-
nist, BN52021, on the course of rejection in a rat renal transplant
model. BN52021 is a specific PAF receptor antagonist that
belongs to a naturally occurring group of compounds known as
ginkolides which are derived from the Ginkgo biloba tree. Ginko-
lides are unique 20 carbon cage molecules, the structure of which
is shown in Figure 1. Because some of the biological effects of
PAP may be mediated through stimulation of other eicosanoids,
we also determined the effect of PAP antagonism on production
of cyclooxygenase and lipoxygenase metabolites of arachidonic
acid by the transplanted kidney.
Methods
Animals
Inbred male rats of the PVG (RT1C) and ACI (RT1) strains
were originally obtained from OLAC Ltd. (Bicester, UK). These
animals were subsequently maintained and bred in an isolated
colony under local and N.I.H. guidelines. All rats were 8 to 12
weeks old when these studies were performed.
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Renal transplantation
Rat renal transplants were performed as previously described
[19] In the allograft groups, kidneys from ACI (RT1) rats were
transplanted into fully allogeneic PVG (RT1C) rats. For the
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Fig. 1. The chemical structure of BN52021. The
compound is a ginkolide which is a family of
unique 20 carbon cage molecules derived from
the Ginkgo biloba tree.
non-rejecting isografts, kidneys from PVG rats were transplanted
into their littermates. The donor kidney, ureter, and bladder were
harvested en bloc, including the renal artery with a 3 mm aortic
cuff and the renal vein with a 3 mm vena caval cuff. These vascular
cuffs were anastomosed to the recipient abdominal aorta and vena
cava, respectively. Total ischemic time averaged 35 to 40 minutes.
Donor and recipient bladders were attached dome to dome. The
right native kidney was removed at time of transplant and the left
native kidney was removed through a flank incision 48 to 72 hours
later. Overall surgical mortality was less than 20% and did not
differ between the experimental groups.
Administration of the PAF antagonist
BN52021 was prepared as a suspension and was administered
by daily subcutaneous injection. A treatment group of rats with
renal allografts (N = 10) received 60 mg/kg/day of BN52021 for
six days beginning immediately prior to transplantation. A control
group of allografts (N = 11) received only vehicle. In previous
studies, similar doses of BN52021 prevented the renal [20] and
systemic [21] effects of exogenous PAF.
Renal fi4nction measurements
To precisely assess renal allograft function, clearances of inulin
and PAH were measured on day 6 following transplantation as
previously described [9, 19]. On the day of study, the animals were
anesthetized with nembutal (20 mg/kg) and a polyethylene cath-
eter (PE-240) was inserted into the trachea to facilitate sponta-
neous respiration. The right carotid artery was cannulated to
permit periodic sampling of arterial blood and measure arterial
blood pressure (BPM-8802, Caldwell Systems, Rougemont, NC,
USA). The jugular vein was cannulated and a volume of normal
saline equal to 1.0% of body wt was infused to replace surgical
losses. Following saline infusion, priming doses of 14C-inulin and
glycyl-3H-PAH (Amersham, Arlington Heights, IL, USA) in
saline were given followed by a continuous infusion at a rate of
0.05 ml/100 g/min. The allograft ureter was cannulated with a
PE-lO catheter.
After a 45-minute equilibration period, urine was collected for
two consecutive 30-minute clearance periods. Arterial blood
samples were obtained at the midpoint of each urine collection.
Tritium and 14C radioactivity were measured in blood and urine
with a dual channel Isocap 300 liquid scintillation counter (Nu-
clear Chicago). Clearances of inulin and PAH were calculated by
standard formulas.
Allograft histopathology
Following the renal hemodynamic studies, a portion of the
transplanted kidney was removed and placed in 10% buffered
formalin. After formalin fixation, the kidney tissue was sectioned
and stained with hematoxylin and eosin (H and E) and periodic
acid-Schiff (PAS) stains. The slides were reviewed by a renal
pathologist (PR) masked to treatment groups and graded as
described previously [19]. The overall severity of rejection was
determined by examining the pattern and intensity of interstitial
inflammation and glomerular, tubular, and vascular abnormali-
ties. The severity of the vascular, tubular, and interstitial abnor-
malities abnormalities were each graded separately using a semi-
quantitative scale from 0 to 4+, where 0 was no abnormality and
4+ represented the most severe abnormality. A total score was
calculated by adding the individual scores.
Eicosanoid measurements
Preparation of renal cortical homogenates. Following renal he-
modynamic studies, animals were sacrificed and kidneys were
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prepared for measurements of renal eicosanoid production and
for histopathologic examination. For the eicosanoid measure-
ments, the transplant kidney was rapidly removed, weighed, and
placed in Kreb's buffer at 4°C. The kidney was then bisected and
a central slice obtained. Cortex was separated from medulla by
macrodissection. Portions of cortex were homogenized and sus-
pended in 2 ml of iced Kreb's buffer. The suspensions were
incubated for 30 minutes at 37°C in 95% 02/5% CO2. Samples
were centrifuged at 2000 rpm for 10 minutes at 4°C and the
supernatants were stored at —70°C until eicosanoids were mea-
sured as described below. The tissue pellet was resuspended in 0.5
ml of cold Kreb's buffer and the protein concentration was
measured using the Coomassie Brilliant Blue dye-binding assay.
Urinaty eicosanoids
HPLC methods. TXB2 and leukotriene metabolites in urine
were extracted and separated by HPLC prior to quantitation by
radioimmunoassay (RIA). Samples were acidified and applied to
C-18 columns preconditioned with methanol and water. After
washing, the samples were eluted with a 70% solution of aceto-
nitrile in water and evaporated to dryness under nitrogen and then
reconstituted in a 1:1 solution of acetonitrile and 2.5 mM trifiuo-
roacetic acid. To separate leukotrienes, a Pecosphere HS3-C18
cartridge (Perkin-Elmer Corp., Norwalk, CT, USA) was used.
Samples and leukotriene standards (Advanced Magnetics Inc.,
Cambridge, MA, USA) were injected onto the column and eluted
with a linear gradient from 100% 2.5 mM trifluoroacetic acid to
100% acetonitrile over eight minutes at a flow rate of 3.0 mi/mm.
Elution of leukotrienes from the column was monitored by
absorbance at wavelength 280 nm with a programmable multi-
wavelength UV spectrophotometer (Waters Associates, Milford,
MA, USA). In this HPLC system, the leukotriene standards for
LTE4 and its major urinary metabolite, N-acetyl-LTE4, were
resolved into closely eluting absorbance peaks; therefore, for
measurement of urinary LTE4 metabolites, a column eluate
fraction was collected over a time interval that included both the
LTE4 and N-Acetyl-LTE4 absorbance peaks at 280 nm. Urinary
TXB2 was separated from other thromboxane metabolites as
described previously [22] using a similar gradient. Elution of
thromboxane metabolites from the column was monitored by
absorbance at a wavelength of 195 nm. All separations were
performed at ambient temperature. Collected fractions were
evaporated to dryness under nitrogen and reconstituted in appro-
priate buffer for quantitation by RIA as described below. Using
this technique, recovery of standards ranged from 40 to 60%.
Radioimmunoassays. TxB2 was quantitated by radioimmunoas-
say as previously described [22]. Antisera and standards were
obtained from AMI-Seragen Inc. (Boston, MA, USA) for the
TxB2. Samples and standards were incubated for 20 minutes with
a mixture of antisera and a known quantity of tritiated standard at
4°C. After incubation, free eicosanoid was adsorbed with dextran
coated charcoal, and tritium remaining in the supernatant was
measured with a liquid scintillation counter (T.M. Analytical, Elk
Grove Village, IL, USA). The unknowns were compared with a
standard curve in which the logarithm of the concentration was
plotted against the logit of the B/B0 value. The concentration of
TXB2 was normalized for protein content of the cortical homo-
genate and is expressed as pg/mm/mg protein.
Concentrations of LTB4 in supernatants from incubations of
renal cortex stimulated by A23 187 was measured by direct RIA as
previously described [9] using a polyclonal antisera (Amersham,
Arlington Hts, IL, USA). Samples (measured in duplicate) and
standards (measured in triplicate) were incubated with known
quantities of [3H]-L1'B4 and antisera at 25°C for two hours. The
concentration of unlabeled LTB4 that inhibited 50% binding of
[3H]LTB4 tracer was 42 7 pg/100 d (mean standard error of
4 assays) and the lower limit of delectability was 0.5 pg/ 100 p.1.
For measurement of peptidoleukotriene excretion in urine,
concentrations of urinary LTE4 metabolites in individual HPLC
fractions were measured using a polyclonal antibody that cross
reacts extensively with LTC4, LTD4, LTE4 and N-acetyl-LTE4 [9].
The concentration of unlabeled LTE4 that inhibited 50% binding
of [3HJLTE4 tracer was 284 19 pg/100 1.d (mean SE of 3
assays) and the lower limit of detectability was 8 pg/lOO p.1. After
incubation for two hours at 4°C, unbound eicosanoids were
removed from the mixture with a suspension of dextran-coated
activated charcoal. Sample concentrations were determined by a
standard curve in which the logarithm of the concentration was
plotted versus the logit of the B/Bo value. Results were expressed
as pg/mm/mg protein. We found that the cross reactivity of the
LTB4 antibody (Amersham) was <1% with LTC4, LTD4, and
LTE4. Cross reactivity of the polyclonal peptidoleukotriene anti-
body with LTB4 was also <1%.
Statistical analysis
Data are presented as mean SEM. For the hemodynamic
studies, data points for each animal represent the mean of the
values measured during at least two clearance periods. For most
comparisons between the vehicle and BN52021 groups, statistical
significance was assessed using an unpaired t-test. The Mann-
Whitney U-test was used in the comparisons of the histopatho-
logic scores.
Results
The effects of PAF receptor inhibition on renal allograft
function six days following transplantation is shown in Figure 2.
Both GFR (1.0 0.4 mi/mm/kg) and RPF (4.0 1.1 mI/mm/kg)
are markedly depressed in the vehicle treated group compared to
levels observed in non-rejecting isografts (GFR 5.8 0.75 ml!
mm/kg; RPF 21.3 3.0 mI/mm/kg). This reflects the aggressive
nature of kidney graft rejection in this model. Treatment with
BN52021 significantly improved GFR (2.1 0.5 ml/min/kg; P <
0.05) and RPF (8.1 1.5 mI/mm/kg; P < 0.025) compared to the
animals which received the vehicle alone. However, following
treatment with the PAF antagonist, renal allograft function did
not reach the level observed in isograft controls. BN52021 had no
effect on blood pressure or hematocrit. Systolic blood pressure in
vehicle animals was 121 4 mm Hg compared to 120 3 mm Hg
in the BN52021 group; hematocrits were 35 1 in the vehicle
group compared to 34 1 in the BN52021 group.
To determine whether the improvement in function induced by
PAF blockade was accompanied by changes in allograft histomor-
phology, we compared the severity of renal histopathologic
changes between the experimental groups. The major pathologic
finding in both groups was severe rejection characterized by an
intense mononuclear cell infiltrate throughout the renal paren-
chyma as shown in Figure 3. There were no detectible differences
in the pattern or severity of the infiltrates between the two groups.
As shown in Table 2, there were no differences between the
treatment and control groups when interstitial, vascular and
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Fig. 2. Effect of BN52021 on renal allograft function. Renal function in the
BN52021 group is shown in the open bars (D) and the control group is
depicted by the hatched bars (a). Treatment with BN52021 significantly
improved GFR and renal plasma flow in rat kidney allografts. (*P < 0.05;
**p < 0.025).
tubular abnormalities were graded separately using a semiquan-
titative scale.
We have previously demonstrated that production of the potent
vasoconstrictor eicosanoid thromboxane A2 (TXA2) by rejecting
allografts mediates a substantial portion of the renal dysfunction
which occurs in this model [8, 19]. To assess the effect of PAF
antagonism on intra-graft thromboxane generation, we measured
production of TXB2, the stable metabolite of TXA2, by homoge-
nates prepared from six day allografts (Table 1). TXB2 production
was significantly reduced from 186 36 pg/mg/mm in controls to
114 15 pg/mg/mm (P < 0.05) with BN52021 treatment. How-
ever, treatment with the PAP antagonist did not reduce throm-
boxane production to the level observed in non-rejecting isografts
(64 14 pg/mg/nun). To assess thromboxane production in vivo,
we measured the excretion of native TXB2 in urine four days after
transplantation. Excretion of unmetabolized TXB2 is thought to
primarily reflect thromboxane production by the kidney [23].
Treatment with BN52021 significantly reduced urinasy TXB2
excretion to 13 2 pg/hr compared to 19 2 pg/hr in controls
(P < 0.05).
In animal models, some of the physiologic effects of PAP
administration can be blocked by inhibiting leukotriene biosyn-
thesis [24—26]. Because we have found that leukotrienes are
important effectors of renal injury in this model [9], we examined
the effects of PAP antagonism on leukotriene production. To
assess the effect of PAP antagonism on the peptidoleukotrienes,
which are potent renal vasoconstrictors, we measured urinary
excretion of the peptidoleukotriene inetabolites LTE4 and N-
acetyl LTE4 (Table 1). Excretion of the LTE4 metabolites in the
BN52021 group was 96 25 pg/hr which was not significantly
different from the value of 102 14 pg/hr seen in controls.
Production of the immunomodulatory eicosanoid LTB4 was mea-
sured in allograft homogenates stimulated with A23 187, and there
were no differences in production of LTB4 by allografts from
animals which received BN52021 (36 5 pg/mg/mm) compared
to controls (32 4 pg/mg/mm).
Discussion
The early events in recognition and initiation of the alloimmune
response involve specific interactions between recipient T cells
and donor alloantigens [1—3]. This specific recognition and T cell
activation generates effector elements which can cause donor-
specific cell killing [27]. As the response develops, inflammatory
mediators are produced which may cause graft injury and dysfunc-
tion in a non-specific fashion. Vasoactive products of inflamma-
tion may be particularly important in the rejection of vascularized
grafts where they can directly influence blood flow and endothelial
cell function. In the current study, we demonstrate that PAP
participates in the development of graft dysfunction during kidney
transplant rejection. In an aggressive model of renal allograft
rejection, we found that specific pharmacologic inhibition of PAP
significantly preserved renal allograft function. PAP inhibition
reduced the generation of the cyclooxygenase metabolite throm-
boxane A2, but had no effect on production of 5-lipoxygenase
metabolites within the graft. Moreover, the beneficial effects of
PAP inhibition on graft function occurred without any detectable
change in renal histology. This suggests that the predominate
Vehicle Group BN52021 Group
Eicosanoid production
by kidney homogenates
pg/mg protein/mm
TXB2 186 36
LTB4 32±4
Urinary eicosanoid
excretion pg/hr
TXB2 19±2
LTE4 metabolites 102 14
a P < 0.05 vs. the vehicle group
114 15
36±5
13±2a
96 25
A
3
E
U-01
0
12
10
E
a)o6C
cci
cci
ci)04I
B
Table 1. Effects of the PAF antagonist on eicosanoid metabolism
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Fig. 3. Histopathology of rat renal allografts six
days after transplantation. This photomicrograph
of an H and F stained section of renal
allografts from vehicle (A) and BN52021
treated (B) rats demonstrates the representative
pathological findings. There were intense
mononuclear cell infiltrates in both groups,
especially in perivascular regions and there
were no differences in the severity or pattern of
histomorphological abnormalities between the
groups. (magnification 100X).
Previous studies have suggested a role for PAF in rejection
responses associated with antibody and complement-dependent
Total vascular injury [28—31]. For example, Ito and colleagues demon-
strated enhanced PAF production by rabbit kidneys undergoing
hyperacute rejection [28]. In their study, markedly elevated PAF
levels were detected in renal venous effluent minutes after revas-
cularization in a pre-sensitized host. In another model of hyper-
acute rejection, Freiche and associates transplanted Brown-Nor-
way rat kidneys into Lewis recipients that were pre-sensitized with
Brown-Norway skin grafts, and showed that pretreatment with a
PAF receptor antagonist markedly improved graft survival [291.
The efficacy of PAF antagonism in xenotransplantation has also
Table 2. Scoring of allograft histological abnormalities
Experimental
groups Interstitium Vasulature Tubules
BN52021 3.1 0.1 1.4 0.2 1.9 0.2 6.4 0.3
(N =9)
Vehicle 3.0 0.2 1.5 0.2 1.9 0.2 6.5 0.8
(N =9)
effect of PAF in this setting is hemodynamic and that PAF has
little influence on the accumulation of immune cells within the
rejecting graft.
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been investigated [30, 31]. While treatment with PAP antagonists
generally decreased complement activation in these models, their
effects on xenograft survival have been inconsistent.
PAP also appears to play a role in rejection of vascularized
organ grafts in non-sensitized hosts. Foegh and colleagues first
demonstrated the efficacy of PAF antagonists in a model of
cardiac allograft rejection [32]. These authors found that
BN52021 given in conjunction with either low dose cyclosporine
or azathioprine improved graft survival in a rat heterotopic
cardiac transplant model. In previous studies, we demonstrated
that PAP production is significantly enhanced in rejecting renal
allografts in rats [33]. Using a platelet aggregation bioassay, we
detected substantial release of bioactive PAF from renal venous
effluent of isolated perfused renal allografts, while PAP release
was not detected in renal isografts. We now show that adminis-
tration of a PAP antagonist with no other immunosuppressive
therapy has significant beneficial effects on renal graft function.
As the benefits of PAP antagonism occur without any change in
the histomorphology of the graft, the mechanism may be hemo-
dynamic and/or involve direct effects on immune cell function.
Cellular immune responses have been considered to be of primary
importance in these rat models of acute rejection; however,
alloantibodies are generated in non-sensitized hosts which may
modulate the course of graft injury [34]. Thus, there may be a
variety of immunological factors that influence PAP production
during rejection.
Prior work has suggested that some of the pro-inflammatory
effects of PAP are mediated through enhanced production of
cyclooxygenase or lipoxygenase metabolites of arachidonic acid
[12, 16-48, 24—26]. In the present study, we found that PAP
inhibition substantially reduced allograft production of thrombox-
ane. This was documented by assessments of thromboxane pro-
duction both in vivo and in vitro. As we have previously established
a role for thromboxane A2 in renal allograft rejection [8, 19], this
suggests that some of the beneficial effects of PAP inhibition in
this model may result from reduced thromboxane production. The
effect of PAP blockade to improve renal hemodynamic function
without altering inflammatory cell infiltration resembles the effect
of thromboxane inhibitors in this model [19]. These findings
emphasize the importance of PAP as a stimulus for thromboxane
production during rejection [17, 18]. However, despite this inhi-
bition of the cyclooxygenase metabolite TXA2, production of
5-lipoxygenase metabolites was not affected by PAP blockade.
Specifically, there were no changes in excretion of the LTE4
metabolites or intra-graft production of LTB4 associated with
BN52021 treatment. This suggests that the cyclooxygenase and
5-lipoxygenase pathways of arachidonic acid metabolism may be
differentially regulated in rejection.
The PAP antagonist caused a significant improvement in renal
allograft function, but function was not restored to the levels seen
in non-rejecting isografts. There are several potential explanata-
tions for this finding. First, there may be an alteration in drug
delivery or efficacy at later stages of rejection. We have observed
a similar phenomenon with thromboxane synthase inhibitors in
this model [19]. Secondly, as discussed above, leukotriene produc-
tion is not affected by BN52021 treatment and leukotrienes are
responsible for a substantial component of renal dysfunction
observed in this model [9]. Also, BN52021 did not completely
suppress thromboxane production to the level seen in isografts,
and this incomplete suppression of thromboxane may further
contribute to graft dysfunction. Finally, renal allograft rejection is
a complex inflammatory response involving a number of effector
systems [1—3]. The benefits of BN52021 treatment on GFR
demonstrate that PAP is one of the factors that produces renal
allograft dysfunction during rejection, albeit not the only one.
In summary, in an aggressive model of acute renal allograft
rejection, administration of the PAP receptor antagonist
BN52021, without any other immunosuppression, led to a marked
improvement in allograft function. This improvement in function
occurred without any significant alteration in the histologic ap-
pearance of the graft. PAP receptor blockade significantly re-
duced production of thromboxane A2 by the graft. However, this
treatment had no effect on leukotriene production. These data
support a role for PAP in the pathophysiology of acute renal
allograft rejection. Moreover, they suggest that the hemodynamic
effects of PAP during rejection may be mediated through stimu-
lation of thromboxane A2. In view of the beneficial effects of PAP
blockade in rejection as well as recent reports describing efficacy
in models of cyclosporine nephrotoxicity [35], PAP antagonists
may have clinical applications in human renal allograft recipients.
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